6533b861fe1ef96bd12c50d2
RESEARCH PRODUCT
Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma
Stephanie HeroldChiara GhiggiGeorg HessTadeusz RobakMatthias TheobaldElke WuffMarie-kristin Tilchsubject
OncologyCancer Researchmedicine.medical_specialtyChemotherapybiologybusiness.industryAnti cd19medicine.medical_treatmentAntigens CD19CancerHematologyImmunotherapyAntibodies Monoclonal Humanizedmedicine.diseaseOncologyTolerabilityRefractoryInternal medicinebiology.proteinHumansMedicineLymphoma Large B-Cell DiffuseAntibodybusinessAdverse effectdescription
Abstract Background: Information about the long-term tolerability of tafasitamab is still limited. Methods: 5 of 92 patients treated within a phase IIa study of single-agent tafasitamab in relapsed or refractory B NHL were followed for up to five years or longer for long-term tolerability. Results: Treatment was very well tolerated in an outpatient setting with no hospitalizations needed and mild and tolerable adverse events that occurred mostly within the first two years of treatment. Conclusions: Given the excellent tolerability and efficacy of tafasitamab this agent can be used to induce remission in relapsed or refractory lymphoma either alone or in combination with chemotherapy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-04-01 | Clinical Lymphoma Myeloma and Leukemia |